 | |
 | |
| Names | |
|---|---|
| Preferred IUPAC name 2-{2,5-Dimethoxy-4-[(2-methoxyethyl)sulfanyl]phenyl}ethan-1-amine | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C13H21NO3S | |
| Molar mass | 271.38 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
2C-T-13 (2,5-dimethoxy-4-(β-methoxyethylthio)phenethylamine) is apsychedelicphenethylamine of the2C family. It was presumably first synthesized byAlexander Shulgin and reported in his bookPiHKAL.[1]
The drug hasstructural properties similar tomescaline and other drugs in the 2C-T series, with the most closely related compounds being2C-T-7 and2C-T-21.
The dosage range of 2C-T-13 is typically 25 - 40mg and its duration is approximately 6–8 hours according toShulgin.[1] 2C-T-13 produces many closed-eye visuals and geometric patterns. It also produces slight visual distortion.[1]
 | This sectionneeds morereliable medical references forverification or relies too heavily onprimary sources. Please review the contents of the section andadd the appropriate references if you can. Unsourced or poorly sourced material may be challenged andremoved.Find sources: "2C-T-13" – news ·newspapers ·books ·scholar ·JSTOR(July 2019) |  |
The mechanism that produces 2C-T-13's hallucinogenic and entheogenic effects has not been specifically established; however, it is most likely to result from action as a5-HT2Aserotonin receptoragonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.
The toxicity of 2C-T-13 is not well documented. 2C-T-13 is slightly less potent than 2C-T-7, but it may be expected that at higher doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.
2C-T-13 is not scheduled in the United States, but possession and sales of 2C-T-13 could be prosecuted under theFederal Analog Act because of its structural similarities to2C-T-7.
As of October 31, 2016, 2C-T-13 is a controlled substance (Schedule III) in Canada.[2]
